Hematologic malignancies are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. Hematologic malignancies originate from uncontrolled growth of hematopoietic and lymphoid tissues, and are commonly classified by their four common subtypes: leukemia, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and multiple myeloma. Hematologic malignancies are relatively common, accounting for around 6.5% of all cancers, and are the fourth most frequently diagnosed cancer in both men and women in economically developed countries.
The incidence of hematologic malignancies varies based on subtype, age, gender, and socioeconomic state. For example, between 1990 and 2017, there was a notable decrease in the age-standardized incidence rate (ASIR) of acute lymphoblastic leukemia (ALL) and a slight decrease in the ASIR of chronic myeloid leukemia (CML) incidence; however, the ASIR of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) has increased in most countries. Furthermore, notable geographical inequalities exist across different regions indicating a deficiency of financial resources, lack of cancer registration centers and resources for diagnosing hematologic malignancies, as well as poor treatment and palliative services. Without an accurate understanding of epidemiological trends in hematologic malignancies, early diagnosis, effective prevention strategies and management cannot be improved.
This Research Topic aims to strengthen the understanding of hematologic malignancy epidemiology to aid in early detection and diagnosis, and improve survival outcomes for patients. We welcome papers focusing on, but not limited to, the following topics:
- Incidence, mortality and survival outcomes for patients with hematologic malignancies
- Genetic risk factors for hematologic malignancies
- Environmental risk factors for hematologic malignancies including occupational risk factors
- The impact of socioeconomic factors for hematologic malignancies
- The quality of life for patients with hematologic malignancies in different settings
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Hematologic malignancies are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. Hematologic malignancies originate from uncontrolled growth of hematopoietic and lymphoid tissues, and are commonly classified by their four common subtypes: leukemia, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and multiple myeloma. Hematologic malignancies are relatively common, accounting for around 6.5% of all cancers, and are the fourth most frequently diagnosed cancer in both men and women in economically developed countries.
The incidence of hematologic malignancies varies based on subtype, age, gender, and socioeconomic state. For example, between 1990 and 2017, there was a notable decrease in the age-standardized incidence rate (ASIR) of acute lymphoblastic leukemia (ALL) and a slight decrease in the ASIR of chronic myeloid leukemia (CML) incidence; however, the ASIR of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) has increased in most countries. Furthermore, notable geographical inequalities exist across different regions indicating a deficiency of financial resources, lack of cancer registration centers and resources for diagnosing hematologic malignancies, as well as poor treatment and palliative services. Without an accurate understanding of epidemiological trends in hematologic malignancies, early diagnosis, effective prevention strategies and management cannot be improved.
This Research Topic aims to strengthen the understanding of hematologic malignancy epidemiology to aid in early detection and diagnosis, and improve survival outcomes for patients. We welcome papers focusing on, but not limited to, the following topics:
- Incidence, mortality and survival outcomes for patients with hematologic malignancies
- Genetic risk factors for hematologic malignancies
- Environmental risk factors for hematologic malignancies including occupational risk factors
- The impact of socioeconomic factors for hematologic malignancies
- The quality of life for patients with hematologic malignancies in different settings
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
